

Janai R. Carr-Ascher, M.D., Ph.D.

Philosophy of Care	Dr. Carr-Ascher is committed to providing comprehensive and innovative care for her patients. She believes that compassion, honesty, and shared decision making are the cornerstones of medical practice. Dr. Carr-Ascher focuses on treating the whole patient while providing high quality evidence based care.
Clinical Interests	Dr. Carr-Ascher is a medical oncologist providing care for adults with cancer. She has an expertise and clinical focus on sarcomas, tumors of connective tissue.
Research/Academic Interests	Dr. Carr-Ascher's research focuses on understanding the biology of sarcoma with the goal of identifying new treatment options. She is working to characterize new ways of studying sarcoma development and metastasis.
Title	Assistant Professor Assistant Professor in Residence
Specialty	Cancer, Molecular Biology/Medicine
Department	Internal Medicine
Division	Hematology and Oncology
Center/Program Affiliation	UC Davis Comprehensive Cancer Center
Address/Phone	UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817 **Phone:** 916-734-5959
Additional Phone	Clinic Fax: 916-703-5265 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., University of Illinois at Chicago, Chicago IL 2013 Ph.D., Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago IL 2013 B.S., UC San Diego, San Diego CA 2002
Residency	Internal Medicine, UC San Francisco, San Francisco CA 2013-2015
Fellowships	Hematology/Oncology, UCLA, Los Angeles CA 2015-2019
Board Certifications	American Board of Internal Medicine
Professional Memberships	American Society of Clinical Oncology American Society of Hematology

UCDAVIS HEALTH



Janai R. Carr-Ascher, M.D., Ph.D.

Honors and Awards

Christine and Helen Landgraf Memorial Research Award, 2021
Chief Fellow, UCLA Specialty Training and Advanced Research (STAR) program, 2018
Resident Teaching Award, 2017
UIC College of Medicine Research Forum Award, 2009
National Ruth Kirshstein Service Award, F31, National Cancer Institute, 2008, 2009, 2010, 2011

Select Recent Publications

Jawad MU, Bayne CO, Farhan S, Haffner MR, Carr-Ascher J, Alvarez E, Thorpe SW, Randall RL. Prognostic factors, disparity, and equity variables impacting prognosis in bone sarcomas of the hand: SEER database review. J Surg Oncol. 2021 Dec;124(8):1515-1522. doi:10.1002/jso.26659. Epub 2021 Aug 25. Erratum in: J Surg Oncol. 2022 Sep;126(4):844. PMID:34432316.

Mukhopadhyay NK, Chand V, Pandey A, Kopanja D, Carr JR, Chen YJ, Liao X, Raychaudhuri P. Plk1 Regulates the Repressor Function of FoxM1b by inhibiting its Interaction with the Retinoblastoma Protein. Sci Rep. 2017 Apr 7;7:46017. doi:10.1038/srep46017. Erratum in: Sci Rep. 2018 Oct 29;8(1):15850. PMID:28387346.

Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR, Franks R, Yu DY, Guzman G, Maker A, Raychaudhuri P. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. J Hepatol. 2015 Aug;63(2):429-36. doi:10.1016/j.jhep.2015.03.023. Epub 2015 Mar 28. PMID:25828473.

Wang Z, Zheng Y, Park HJ, Li J, Carr JR, Chen YJ, Kiefer MM, Kopanja D, Bagchi S, Tyner AL, Raychaudhuri P. Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma. Mol Cancer Ther. 2013 May;12(5):759-67. doi:10.1158/1535-7163.MCT-12-0903. Epub 2013 Feb 20. PMID:23427295.

Carr JR, Kiefer MM, Park HJ, Li J, Wang Z, Fontanarosa J, DeWaal D, Kopanja D, Benevolenskaya EV, Guzman G, Raychaudhuri P. FoxM1 regulates mammary luminal cell fate. Cell Rep. 2012 Jun 28;1(6):715-29. doi:10.1016/j.celrep.2012.05.005. Epub 2012 Jun 7. PMID:22813746.

UCDAVIS HEALTH



Janai R. Carr-Ascher, M.D., Ph.D.

Wang Z, Park HJ, Carr JR, Chen YJ, Zheng Y, Li J, Tyner AL, Costa RH, Bagchi S, Raychaudhuri P. FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. Cancer Res. 2011 Jun 15;71(12):4292-302. doi:10.1158/0008-5472.CAN-10-4087. Epub 2011 Apr 20. PMID:21507930.

Park HJ, Gusarova G, Wang Z, Carr JR, Li J, Kim KH, Qiu J, Park YD, Williamson PR, Hay N, Tyner AL, Lau LF, Costa RH, Raychaudhuri P. Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med. 2011 Jan;3(1):21-34. doi:10.1002/emmm.201000107. Epub 2010 Dec 17. PMID:21204266.

Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 2010 Jun 15;70(12):5054-63. doi:10.1158/0008-5472.CAN-10-0545. Epub 2010 Jun 8. PMID:20530690.

Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF, Costa RH, Raychaudhuri P. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009 Oct 7;28(19): 2908-18. doi:10.1038/emboj.2009.239. Epub 2009 Aug 20. PMID:19696738.

Oppegard SC, Nam KH, Carr JR, Skaalure SC, Eddington DT. Modulating temporal and spatial oxygenation over adherent cellular cultures. PLoS One. 2009 Sep 3;4(9):e6891. doi:10.1371 /journal.pone.0006891. PMID:19727397.

© 2024 UC Regents

UCDAVIS HEALTH